Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Nihon Ronen Igakkai Zasshi ; 60(1): 60-66, 2023.
Artigo em Japonês | MEDLINE | ID: mdl-36889724

RESUMO

A 75-year-old man visited our Collagen Disease Department because of a fever, edema in the lower legs, and arthralgia. He presented with peripheral arthritis of the extremities and was negative for rheumatoid factor, leading to a diagnosis of RS3PE syndrome. A search for malignancy was performed, but no obvious malignant findings were found. After starting treatment with steroid, methotrexate, and tacrolimus, the patient's joint symptoms improved, but after five months, enlarged lymph nodes throughout the body were observed. A lymph node biopsy revealed a diagnosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders/angioimmunoblastic T-cell lymphoma (OI-LPD/AITL). After discontinuation of methotrexate and follow-up, no lymph node shrinkage was observed, and the patient had strong general malaise, so chemotherapy was started for AITL. After the start of chemotherapy, the patient's general symptoms improved quickly. RS3PE syndrome is a polyarticular, rheumatoid factor-negative, polyarticular synovitis with symmetric dorsolateral hand-palmar symmetric indentation edema that occurs mainly in elderly patients. It is also noted as a paraneoplastic syndrome, with 10%-40% of patients having malignant tumors. When our patient was diagnosed with RS3PE syndrome, a search for malignancy was performed, but there were no findings suggestive of malignant disease. However, after methotrexate and tacrolimus administration was started, the patient developed rapid lymph node enlargement, and the pathology showed AITL. The possibility of AITL as an underlying disease and RS3PE syndrome as a paraneoplastic syndrome, or conversely, OI-LPD/AITL associated with immunosuppressive therapy for RS3PE syndrome is considered. We herein report this case, as sufficient recognition is required for a proper diagnosis to be made and treatment of RS3PE syndrome to be performed.


Assuntos
Linfadenopatia Imunoblástica , Linfoma de Células T , Síndromes Paraneoplásicas , Masculino , Humanos , Idoso , Metotrexato , Fator Reumatoide , Tacrolimo/uso terapêutico , Linfadenopatia Imunoblástica/complicações , Linfadenopatia Imunoblástica/tratamento farmacológico , Linfadenopatia Imunoblástica/patologia , Síndromes Paraneoplásicas/complicações , Síndromes Paraneoplásicas/diagnóstico , Edema/complicações , Edema/diagnóstico , Linfoma de Células T/complicações , Linfoma de Células T/tratamento farmacológico , Terapia de Imunossupressão
2.
Nihon Ronen Igakkai Zasshi ; 58(2): 284-289, 2021.
Artigo em Japonês | MEDLINE | ID: mdl-34039805

RESUMO

Primary effusion lymphoma (PEL) is a large B-cell lymphoma that only proliferates proliferating effusion in the body cavity. It is associated with human herpesvirus 8 (HHV8).HHV8 negative effusion lymphoma, which is different from PEL in many ways, has also been reported and is referred to as HHV8-unrelated PEL-like lymphoma. This lymphoma is very rare and its clinical characteristics have not been fully clarified.A 79-year-old male developed HHV8-negative primary effusion lymphoma during treatment for myelodysplastic syndrome.Abdominal computed tomography revealed abdominal effusion, but did not show any evidence of a tumor mass or lymph node enlargement. A cytological analysis of his pleural effusion revealed atypical lymphoid cells that were negative for CD10, and positive for CD19 and CD20. Corticosteroids were administered to treat the abdominal effusion; however, the patient died of an exacerbation of lymphoma on the 20th day after the initiation of corticosteroid therapy. We herein report the case of an HIV seronegative elderly patient with HHV8-unrelated PEL-like lymphoma.


Assuntos
Herpesvirus Humano 8 , Linfoma Difuso de Grandes Células B , Linfoma de Efusão Primária , Síndromes Mielodisplásicas , Idoso , Humanos , Linfoma de Efusão Primária/tratamento farmacológico , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA